| Schedule of Segment Reporting Information |
Net sales and profit by each reportable segment for the three and six months ended June 30, 2026 and 2025 are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2026 | | Six Months Ended June 30, 2026 | | Dollars in thousands | Specialty Surgery | | Tissue Reconstruction | | Corporate and Other | | Total | | Specialty Surgery | | Tissue Reconstruction | | Corporate and Other | | Total | | Total revenue, net | $ | 309,269 | | | $ | 109,492 | | | $ | — | | | $ | 418,761 | | | $ | 592,404 | | | $ | 218,275 | | | $ | — | | | $ | 810,679 | | | | | | | | | | | | | | | | | | | Cost of goods sold | 130,212 | | | 41,989 | | | 26,816 | | | 199,017 | | | 240,687 | | | 79,448 | | | 53,818 | | | 373,953 | | | Research and development | 14,200 | | | 8,169 | | | 1,884 | | | 24,253 | | | 26,053 | | | 15,701 | | | 6,000 | | | 47,754 | | | Selling, general & administrative | 75,983 | | | 40,394 | | | 56,059 | | | 172,436 | | | 153,664 | | | 83,920 | | | 113,087 | | | 350,671 | | | Intangible asset amortization | — | | | — | | | 3,770 | | | 3,770 | | | — | | | — | | | 7,546 | | | 7,546 | | | | | | | | | | | | | | | | | | | Total cost and expenses | 220,395 | | | 90,552 | | | 88,529 | | | 399,476 | | | 420,404 | | | 179,069 | | | 180,451 | | | 779,924 | | | | | | | | | | | | | | | | | | | Operating income (loss) | 88,874 | | | 18,940 | | | (88,529) | | | 19,285 | | | 172,000 | | | 39,206 | | | (180,451) | | | 30,755 | | | Interest income | | | | | | | 4,267 | | | | | | | | | 8,372 | | | Interest expense | | | | | | | (22,994) | | | | | | | | | (45,459) | | | Other income, net | | | | | | | 4,186 | | | | | | | | | 8,665 | | | Income before income taxes | | | | | | | $ | 4,744 | | | | | | | | | $ | 2,333 | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2025 | | Six Months Ended June 30, 2025 | | Dollars in thousands | Specialty Surgery | | Tissue Reconstruction | | Corporate and Other | | Total | | Specialty Surgery | | Tissue Reconstruction | | Corporate and Other | | Total | | Total revenue, net | $ | 303,958 | | | $ | 111,647 | | | $ | — | | | $ | 415,605 | | | $ | 584,622 | | | $ | 213,636 | | | $ | — | | | $ | 798,258 | | | | | | | | | | | | | | | | | | Cost of goods sold (1) | 120,243 | | | 56,660 | | | 29,370 | | | 206,273 | | | 230,104 | | | 105,930 | | | 58,460 | | | 394,494 | | Research and development (1) | 14,627 | | | 6,770 | | | 5,600 | | | 26,997 | | | 29,423 | | | 12,741 | | | 9,561 | | | 51,725 | | Selling, general & administrative (1) | 83,174 | | | 44,310 | | | 52,406 | | | 179,890 | | | 166,962 | | | 86,614 | | | 107,811 | | | 361,387 | | | Intangible asset amortization | — | | | — | | | 3,754 | | | 3,754 | | | — | | | — | | | 7,458 | | | 7,458 | | | Goodwill impairment | 388,106 | | | 123,259 | | | — | | | 511,365 | | | 388,106 | | | 123,259 | | | — | | | 511,365 | | | Total cost and expenses | 606,150 | | | 230,999 | | | 91,130 | | | 928,279 | | | 814,595 | | | 328,544 | | | 183,290 | | | 1,326,429 | | | | | | | | | | | | | | | | | | | Operating loss | $ | (302,192) | | | $ | (119,352) | | | (91,130) | | | (512,674) | | | $ | (229,973) | | | $ | (114,908) | | | $ | (183,290) | | | (528,171) | | | Interest income | | | | | | | 4,710 | | | | | | | | | 9,130 | | | Interest expense | | | | | | | (21,042) | | | | | | | | | (39,857) | | | Other income, net | | | | | | | (1,946) | | | | | | | | | (2,090) | | | Loss before income taxes | | | | | | | $ | (530,952) | | | | | | | | | $ | (560,988) | | | | | | | | | | | | | | | | | |
(1) The amounts reported for the three and six months ended June 30, 2025 have been retrospectively recast to reflect the realignment of certain cost and expense information as discussed in Note 1. Basis of Presentation.
|